Altre lingue Acelyrin, Inc.

Azioni

SLRN

US00445A1007

Tempo reale stimato Cboe BZX Altri mercati azionari 20:10:18 24/05/2024			Variaz. 5gg	Var. 1 gen.
4,075 ^USD	-3,44%		-6,95%	-45,24%

22/05	ACELYRIN, INC. : prospettiva positiva di HC Wainwright	ZM
09/05	Acelyrin, Inc. annuncia che Ron Oyston si dimetterà dalla carica di Chief People Officer, con effetto dal 15 agosto 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	09/05
ACELYRIN, INC. Announces Leadership Transition	09/05
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones	09/05
Acelyrin, Inc. Announces CEO Changes	09/05
Acelyrin, Inc. Announces Leadership Transition	09/05
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024	29/04
Affibody publishes Annual Report 2023	19/04
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	05/04
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights	28/03
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights	28/03
North American Morning Briefing : Stocks Struggle After New Records	22/03
Sector Update: Health Care Stocks Ease Late Afternoon	20/03
Sector Update: Health Care	20/03
Acelyrin Shares Rise After Lonigutamab Shows Clinical Responses in Thyroid Eye Disease Trial	20/03
Acelyrin : Corporate Presentation	20/03
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	20/03
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	20/03
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	20/03
Sector Update: Health Care Stocks Softer Late Afternoon	11/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Acelyrin, Inc.

Azioni

SLRN

US00445A1007

Altre lingue

Filtri